261 related articles for article (PubMed ID: 21210112)
1. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.
Pfluger T; Melzer HI; Schneider V; La Fougere C; Coppenrath E; Berking C; Bartenstein P; Weiss M
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):822-31. PubMed ID: 21210112
[TBL] [Abstract][Full Text] [Related]
2. Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.
Schramm N; Rominger A; Schmidt C; Morelli JN; Schmid-Tannwald C; Meinel FG; Reiser MF; Rist C
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1014-24. PubMed ID: 23503574
[TBL] [Abstract][Full Text] [Related]
3. Is there any additional benefit of contrast-enhanced CT as part of routine PET/CT protocols for the differentiation of suspicious incidental gastrointestinal 2-deoxy-(18)F-FDG uptake?
Brendle CB; Aschoff P; Kratt T; Schraml C; Reimold M; Claussen CD; Pfannenberg CA
Korean J Radiol; 2013; 14(6):951-9. PubMed ID: 24265572
[TBL] [Abstract][Full Text] [Related]
4. Value of FDG PET/Contrast-Enhanced CT in Initial Staging of Colorectal Cancer - Comparison with Contrast-Enhanced CT.
Kunawudhi A; Sereeborwornthanasak K; Promteangtrong C; Siripongpreeda B; Vanprom S; Chotipanich C
Asian Pac J Cancer Prev; 2016; 17(8):4071-5. PubMed ID: 27644663
[TBL] [Abstract][Full Text] [Related]
5. No clinically relevant differences between positron emission tomography (PET) reconstructions based on low-dose or contrast-enhanced CT in combined integrated multiphase (18) F-Fluorethylcholine PET/CT for prostate cancer.
Behrendt FF; Lensing C; Keil S; Mottaghy FM; Verburg FA
J Med Imaging Radiat Oncol; 2016 Aug; 60(4):498-505. PubMed ID: 27297449
[TBL] [Abstract][Full Text] [Related]
6. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
Nayak B; Dogra PN; Naswa N; Kumar R
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
[TBL] [Abstract][Full Text] [Related]
7. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer.
Okada M; Murakami T; Kumano S; Kuwabara M; Shimono T; Hosono M; Shiozaki H
Ann Nucl Med; 2009 Jan; 23(1):73-80. PubMed ID: 19205841
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography.
Altini C; Niccoli Asabella A; Di Palo A; Fanelli M; Ferrari C; Moschetta M; Rubini G
Medicine (Baltimore); 2015 May; 94(20):e864. PubMed ID: 25997066
[TBL] [Abstract][Full Text] [Related]
9. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET).
Albanus DR; Apitzsch J; Erdem Z; Erdem O; Verburg FA; Behrendt FF; Mottaghy FM; Heinzel A
Eur J Radiol; 2015 Oct; 84(10):1866-72. PubMed ID: 26152870
[TBL] [Abstract][Full Text] [Related]
11. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of combined PET/CT to assess regional lymph node involvement in gastric cancer.
Park K; Jang G; Baek S; Song H
Tumori; 2014; 100(2):201-6. PubMed ID: 24852866
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas.
Niccoli-Asabella A; Altini C; Notaristefano A; Merenda N; Altieri ML; Stabile-Ianora AA; Fanelli M; Rubini G
Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of FDG uptake in pulmonary hila with FDG PET/CT and contrast-enhanced CT in patients with thoracic and non-thoracic tumors.
Gedik GK; Kara PO; Kara T; Sari O; Kara F
Ann Nucl Med; 2010 Oct; 24(8):593-9. PubMed ID: 20665251
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic value of ¹⁸F-fluorodexyglucose positron emission tomography combined with contrast enhanced computed tomography in colorectal cancer liver metastasis].
Zhang Z; Lyu Q; Chen F; Liao S; Zhang J; Hu R; Hu P
Zhonghua Wei Chang Wai Ke Za Zhi; 2015 Mar; 18(3):238-42. PubMed ID: 25809326
[TBL] [Abstract][Full Text] [Related]
19. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
20. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
